期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

SIRT1在糖尿病及其并发症中的研究进展及治疗潜力

下载PDF
导出
摘要 SIRT1即沉默信息调节因子1是依赖于烟酰胺腺嘌呤二核苷酸（NAD＋）的组蛋白脱乙酰化酶，它参与糖代谢和胰岛素的分泌过程。SIRT1基因沉默或蛋白抑制导致SIRT1下调可以诱导胰岛素抵抗（IR），增加SIRT1的表达尤其是在IR的情况下，可以增加胰岛素的敏感性，促进胰岛素分泌，降低血浆葡萄糖的含量，从而改善胰岛素抵抗，成为治疗糖尿病的新潜在靶点。
作者 郭淑芹 朱春英 张云良
机构地区 河北省保定市第一中心医院
出处 《河北医药》 CAS 2011年第20期3145-3147,共3页 Hebei Medical Journal
关键词 SIRT1 糖尿病 胰岛素抵抗 并发症 治疗潜力
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献23

  • 1Tatar M,Bartke A,Antebi A. The endocrine regulation of aging by insulin-like signals. Science ,2003,299 : 1346-1351.
  • 2Rodgers JT. Nutrient control of glucose homeostasis through a complex of PGC-1 a and SIRTI. Nature ,2005,434 : 113-118.
  • 3Sun C. SIRT1 improves insulin sensitivity under msulin-reslstant conditions by repressing PTP l B. Cell,2007,6 : 307-319.
  • 4Li X. SIRT1 deaeetylates and positively regulates the nuclear receptor LXR. Mol Cell ,2007,28:91-106.
  • 5Boily G. SirT1 regulates energy metabolism and response to caloric restriction in mice. PLo SONE,2008,3 :e1759.
  • 6Luo J, Nikolav AY, Imai S, et al. Negative control of p53 by Sir-alpha promotes cell survival under stress. Cell,2001,107:137-148.
  • 7Kume S,Uzu T,Kashiw Agi A,et al. SIRT1 ,a calorie Restriction Mimetic, in a New Therapeutic Appriach for type 2 diabetes mellitus and diabetic vascular complication. Endocr Metab Immune Disord Drug Target,2010,10 : 16-24.
  • 8Rutanen J, Yaluri N, Modi S, et al. SIRT1 mRNA expression may be associated with energy expenditure and insulin sensitivity. Diabetes, 2010,59:829-835.
  • 9Anne B, Lora BS, Fitzhugh SJ, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science ,2004,303:2011- 2015.
  • 10Rodgers JT, Puigserver P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuinl. Proceedings of the National Academy of Science ,2007,104 : 12861-12866.

二级参考文献26

  • 1Hu DY,Pan CY,Yu JM,for the China Heart Survey Group.The relationship between coronary artery disease and abnormal glucose regulation in China:the China Heart Survey.Eur Heart J,2006,27:2573-2579.
  • 2Bartnik M,Ryden L,Ferrari R,et al.The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe:the Euro Heart Survey on diabetes and the heart.Eur Heart J,2004,25:1880-1890.
  • 3Stern MP.Diabetes and cardiovascular disease.The "common soil" hypothesis.Diabetes,1995,44(4):369-374.
  • 4Barr EL,Zimmet PZ,Welborn TA,et al.Risk of Cardiovascular and All-Cause Mortality in Individuals With Diabetes Mellitus,Impaired Fasting Glucose,and Impaired Glucose Tolerance The Australian Diabetes,Obesity,and Lifestyle Study (AusDiab).Circulation,2007,116:151-157.
  • 5Norhammar A,Malmberg K,Diderholm E,et al.Diabetes mellitus:The major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization.J Am Coll Cardiol,2004,43:585-591.
  • 6Tamita K,Katayama M,Takagi T,et al.Impact of Newly Diagnosed Abnormal Glucose Tolerance on Long-Term Prognosis in Patients With Acute Myocardial Infarction.Circ J,2007,71:834-841.
  • 7DECODE Study Group,the European Diabetes Epidemiology Group.Glucose tolerance and cardiovascular mortality:Comparison of fasting and 2-hour diagnostic criteria.Arch Intern Med,2001,161:397-405.
  • 8Pan XR,Li GW,Hu YH,et al.Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and Diabetes Study.Diabetes Care,1997,20:537-544.
  • 9Chiasson JL,Josse RG,Gomis R,et al.Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance:The STOPNIDDM trial.JAMA,2003,290:486-494.
  • 10Bartnik M,Ryde′n L,Malmberg KO,et al.On behalf of the Euro Heart Survey Investigators.Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease.Heart,2007,93:72-77.

共引文献22

河北医药
2011年 第20期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部